Treating herpesvirus-mediated intestinal dysfunction for prevention of age-related neurodegeneration
AssigneeBattle Biotech L.L.C.
InventorRichelle Cutler Strom
Life of this patent
Estimating the term…
Loading patent…
AssigneeBattle Biotech L.L.C.
InventorRichelle Cutler Strom
Estimating the term…
Human herpesviruses can infect barrier and immune cells of the intestines to cause microbiome dysbiosis and inflammation. Microbiome dysbiosis can affect the brain function, and inflammation can compromise the intestinal barrier and lead to microbial translocation. Embodiments may restrict herpesvirus activity and injury by 1) the oral administration of exosomes containing factors to inhibit viral activity and restore homeostasis, and 2) the oral administration of recombinant bacteria that produce exosomes containing factors to inhibit viral activity and restore homeostasis. Embodiments also measure HHV activity in stool by ELISA immunoassay of HHV proteins.
1-20. (canceled)
A method of preventing or treating HHV-mediated dysfunction in mammals by oral administration of exosomes containing antiviral factors comprised of miRNA, shRNA, siRNA, mRNA, oligonucleotides, and protein.
A method of preventing or treating HHV-mediated dysfunction, the method comprising:
A method for measuring HHV activity by detecting herpesvirus tegument proteins SEQ ID NO:35 VP22, SEQ ID NO:36 pp150, and SEQ ID NO:37 pp65 in stool samples.
Dependencies are inferred from the claim text.